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Prospects for Optogenetic
Augmentation of Brain Function
Sarah Jarvis and Simon R. Schultz *
Centre for Neurotechnology and Department of Bioengineering, Imperial College London, London, UK
The ability to optically control neural activity opens up possibilities for the restoration
of normal function following neurological disorders. The temporal precision, spatial
resolution, and neuronal specificity that optogenetics offers is unequalled by other
available methods, so will it be suitable for not only restoring but also extending brain
function? As the first demonstrations of optically “implanted” novel memories emerge, we
examine the suitability of optogenetics as a technique for extending neural function. While
optogenetics is an effective tool for altering neural activity, the largest impediment for
optogenetics in neural augmentation is our systems level understanding of brain function.
Furthermore, a number of clinical limitations currently remain as substantial hurdles
for the applications proposed. While neurotechnologies for treating brain disorders
and interfacing with prosthetics have advanced rapidly in the past few years, partially
addressing some of these critical problems, optogenetics is not yet suitable for use
in humans. Instead we conclude that for the immediate future, optogenetics is the
neurological equivalent of the 3D printer: its flexibility providing an ideal tool for testing
and prototyping solutions for treating brain disorders and augmenting brain function.
Keywords: optogenetics, neural augmentation, neural coding and decoding, neural engineering, neural
modulation, neural prosthetics, BMI (brain machine interface)
1. INTRODUCTION
Combining genetic targeting with optical excitation, optogenetics offers the ability to not only
record the activity of large populations of neurons but also manipulate the activity of individual
cells. Recording neural activity is achieved by selective expression of activity sensitive fluorophores
(such as those from the GCaMP and VSFP protein families, reviewed by Knöpfel, 2012) into
neurons, whose activity can then be read out by optical imaging.Manipulation of neural activity can
be achieved via the insertion of light-sensitive proteins (opsins) that act as ion channels or pumps
into a neuron’s membrane and are preferentially controlled by photons of different wavelengths,
providing temporal control on the order of milliseconds. Together, this cell type specificity and
temporal control results in a tool that can perturb neural circuits with high precision. Since its first
application to neural populations in 2005 (Boyden et al., 2005), it has already had substantial impact
as a popular technique within the neuroscientific toolkit.
In addition to its use as a research tool, optogenetic stimulation has been suggested as a
new approach for neuroprosthetics and treatment of brain disorders. While therapies in these
domains have traditionally used electrical or pharmacological techniques, optogenetics has one
particular advantage over electrical stimulation in being able to target specific cell classes through
gene expression. As a result, specific neuronal populations can in principle be controlled without
potential brain-wide, side effects. Likewise, the extremely fine temporal precision it offers on the
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scale of milliseconds, due to its optical activation, has the
advantage over pharmacology of not only acting immediately
but also having no washout time. Together, these characteristics
have led to optogenetics to be proposed as a viable approach
for improved deep brain stimulation (Kravitz et al., 2010),
reinstatement of functionality following spinal cord injury
(Alilain et al., 2008) and retinal prostheses (Degenaar et al.,
2009; Busskamp et al., 2012), amongst other potential clinical
applications in humans, following studies using mice, rats and
non-human primates as animal models.
The blurred boundary between restoring function and
functional enhancement is present for any biomedical
intervention. From improving existing function to the
incorporation of new streams of information, augmentation
of the central nervous system raises specific challenges, from
technical issues that are shared with the development of neural
therapies, to the more fundamental difficulty of identifying
where and how to best modify existing activity to move to the
new neural trajectory. In addition, the ethics of the benefits
and unintended consequences of intervening in the brain are
substantial, as discussed in a recent report by the Nuffield
Council on Bioethics 2013.
Does the usefulness of optogenetics as a tool for
probing neural circuits automatically translate to its use
for neuroaugmentation? Or instead, is it at best limited to
the rapid prototyping of novel approaches for enhancing
neural processing, much like 3D printers have accelerated for
the development of biomedical devices such as prosthetics
(including ears, prosthetics and sockets), with the benefit of
allowing easy customization? In this article, we examine how
well suited is it as a tool for improving, and not merely probing,
neural function. By identifying the advantages optogenetics
offers over traditional tools for treatment of dysfunction, as well
as the hurdles facing neuroaugmentation, we evaluate the use of
optogenetics as a practical tool for neural enhancement.
2. OPTOGENETIC TREATMENT AND
NEUROPROSTHETICS
A long-held goal of neuroscience has been to identify the
specific roles that various neuronal populations play in neural
information processing, in order to develop novel therapeutic
approaches for brain disorders. The development of light
sensitive tools, including opsins and optically activated G
protein–coupled receptors (GPCRs), has provided an exceptional
tool with which to dissect out the roles of neuronal populations.
Critically, their specificity to target neurons by neuronal class and
location is a unique advantage, and the ability to test without
inducing irreversible changes allows confirmation without long-
term damage. In rodent models, optogenetics has been used for
investigating disorders such as Parkinson’s Disease (Gradinaru
et al., 2010), drug addiction (Witten et al., 2010), epilepsy
(Bernstein and Boyden, 2011; Tye and Deisseroth, 2012), post-
traumatic stress disorder (Sparta et al., 2013) and obesity
(Krashes and Kravitz, 2014), among others. Subsequently,
refining our understanding of neuronal processing has led to
improving treatments by either refining the stimulation protocol
or identifying a different target population.
The potential of optogenetics as a more finely targeted
alternative to traditional neuromodulatory treatments, such as
deep brain stimulation (DBS), has led to the development
of optical DBS in rodent models (Aravanis et al., 2007) and
proposals for its use in primates (Han and Boyden, 2007;
Han, 2012). More recently, combining optical DBS with online
monitoring of state has been possible: By integrating optogenetics
with fMRI (Lee et al., 2010; Kahn et al., 2013), thus providing
the critical link for evaluating the efficacy of the intervention.
Specifically, this has been utilized to evaluate the use of
optogenetics for the effective control of epileptic seizures, thus
allowing the development of less disruptive interventions for
temporal lobe epilepsy than are currently clinically available
(Armstrong et al., 2013; Krook-Magnuson et al., 2013).
The ability to either increase or decrease activity is an essential
aspect of making defined manipulations of targeted elements
of the cortical circuit. However, identifying the optimal opsin
for a given effect and target neuronal population is challenging.
This is illustrated by the recent history of the development of
optogenetic retinal prostheses. Originally, channelrhodopsin-2,
an excitatory opsin, was proposed to be used to replace function
in the retinal ganglion cells layers in conditions such as Retinitis
Pigmentosa (RP) and Macular Degeneration (MD). Despite
initially promising reports (reviewed in Busskamp et al., 2012), a
later study concluded that channelrhodopsin-2 (ChR2) lacks the
necessary sensitivity to make its use in a retinal prosthesis viable
(Lagali et al., 2008). Soon after, halorhodopsin, an inhibitory
opsin, was instead targeted to the photoreceptors. By changing
the targeted circuit element, and sign of the perturbation applied,
it was possible to significantly improve performance (Busskamp
et al., 2010). Given that the retinal circuit has been mapped and
extensively studied, this highlights the difficulty in identifying
the optimal population to be targeted for even relatively simple
networks.
The prospect of viable optically targeted treatments has been
further advanced by the development of opsins that have effects
beyond their immediate photoactivation, such as step-function
opsins (SFO; Berndt et al., 2009) and stabilized step-function
opsins (SSFO; Yizhar et al., 2011) that are able to sustain a
photocurrent for longer durations (on the order of 30min) before
deactivation via illumination at another wavelength. These opsins
thus offer the potential to alter the balance between excitation and
inhibition over long-time scales. By doing so over large cortical
areas, they offer the possibility to modulate activity which make
them suited for treating conditions that are characterized gain
dysfunction, such as depression, anxiety, autism, schizophrenia
and attention deficit disorders (Yizhar et al., 2011), while
minimizing the need for sustained activation. Independently of
other clinical hurdles, the reality of this approach hinges on
the stability of SFO and SSFOs to sustain a photocurrent over
far longer durations, which drastically limits its potential as a
therapy in itself. However, a substantial advantage of these opsins
is that the strength of their modulation is dependent on the
irradiance, which could provide a effective method by which to
evaluate the magnitude of the shift required to restore healthy
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neural functioning, thus indirectly assisting in the development
of alternative therapies.
A further use of optogenetics exploits its ability for altering
neural activity with high temporal precision. By using short, well-
timed pulses, it is possible to not only induce short-term plasticity
but also induce long-term potentiation and/or depression
(Zhang and Oertner, 2006). This suggests the possibility of
reprogramming circuits by either strengthening or weakening
connections (Gu and Yakel, 2011; Larsen et al., 2014). The same
technique has also been applied to promote regrowth following
peripheral nerve injury (Li et al., 2011).
Together, these studies demonstrate that optogenetic
technology has many useful properties, including specificity for
targeting neuronal populations, activation flexibility due to the
range of opsins available, and excellent spatiotemporal control.
Given this, we now examine how well suited optogenetics is for
augmenting brain function.
3. EXTENDING NEURAL FLOW OF
INFORMATION THROUGH OPTICAL
CONTROL
Neural augmentation technologies aim to enhance the
cognitive capacity or sensorimotor function of the brain.
The underlying principles here are conceptually similar to those
of neuroprosthetics, in that they both involve altering neural
activity or neural circuits in order to redefine input-output
relationships. However, there is a fundamental difference.
Replacing functionality requires only a crude approximation of
absent activity, while enhancement can involve either refining
existing activity whilst preserving the brain’s ability to process
existing signals, or alternatively incorporating new streams
of information, thus allowing a neuron to sample input from
additional stimuli. The difficulty in interfacing with the CNS
whilst preserving natural activity can be observed even at the
single cell level. In optogenetics, using high levels of illumination
lead to optical initiation of an action potential that effectively
overrides the neuron’s behavior, so that it produces a spike
irregardless of its inputs. A subtler approach to integrating
additional signals into the nervous system might instead
superimpose such signals onto the existing inputs to the neuron,
thus allowing the addition of new information streams into
neural circuits without necessarily disrupting the processing of
existing streams.
The obstacle of effectively blending information in the
brain is well-illustrated in the history of the visual prosthesis.
Following earlier observations that applying electrical current
to the occipital lobe resulted in the perception of phosphenes
(Foerster, 1929), the first visual prosthesis was implanted into
the cortex (Brindley and Lewin, 1968), preceding the first retinal
prosthesis by nearly a decade (Dawson and Radtke, 1977).
Despite improvements to electrode design in the decades since,
such as increasing the density of cortical electrodes, as well as an
ever-increasing understanding of the visual system, cortical visual
prostheses have not yet matched the clinical success of retinal
prostheses (Eiber et al., 2013), highlighting the difficulties of
artificially altering neural activity within the brain. This is despite
the presence of organizational features of the visual cortical
areas, such as the retinotopic map, providing a topography
for mapping information onto the surface of the cortex which
could be coopted for brain-machine interfacing purposes. As
one progresses synaptically further from the retina, visual
information is organized along more complex—and generally
less well understood—dimensions. Consequently, the lack of
a well-understood topographic map makes neural interfacing
with association areas more difficult. This is even more true of
higher cortical areas, such as the prefrontal cortex, which receive
information from multiple areas. Thus, although information
relating to our interaction with the worldmay bemapped in some
kind of ordered fashion onto its surface, our understanding of
that map is incomplete and we are therefore currently unable to
exploit it for brain augmentation.
However, there is evidence demonstrating that optogenetic
manipulation for augmenting simple stimuli is possible. In a
recent study, mice were trained to discriminate the location of
a bar during whisking (O’Connor et al., 2013). After identifying
the coding scheme used within the barrel cortex to encode the
location of the bar stimulus, optogenetic perturbations were
then applied that would encode, if successful, for the other
potential position. The mice reported the bar in the incorrect
(virtual) location. While this study was important for the insight
it provided into the mechanisms of whisker stimulus encoding, it
also provides us with a glimpse into the possibilities provided by
illusionary or virtual stimuli. If it is possible to optically signal
a false bar position during whisking, then it also hints at the
potential of refining sensory inputs based upon additional, non-
biological sensors—or potentially even of integrating entirely
new sensory inputs into conscious awareness. For instance, it may
be possible to augment conscious perception with input from
non-visible parts of the electromagnetic spectrum, in order to
provide additional sensory capability for working in dangerous
environments (Figure 1A).
Augmenting sensory function supplies additional input to
the relevant sensory cortex and require a detailed topological
map of the neural organization. Similarly, motor outputs can
be remapped onto robotic manipulators, allowing augmented
motor functionality for external actuators. Neuroprostheses for
augmenting motor functionality might use open-loop systems,
requiring only the reading of signals from motor cortex.
However, closed loop neural interfaces have proved to be
important for making BMI a completely integrated replacement
for motor function (Donoghue, 2002). In the context of
optogenetic brain augmentation, this might involve a fully
optical system (e.g., reading out signals from motor cortex using
optical imaging of a genetically encodable calcium indicator,
together with writing feedback signals into, for instance,
somatosensory cortex using optical stimulation of opsins). This
potentially also opens up the opportunity to improve learning by
augmenting the trajectory error, which provides vital feedback
during normal motor learning tasks (Figure 1B). Studies have
shown that for gross movements, both error amplification
and offsetting improve the amount and speed of adaptation
during motor learning, using protocols normally targeted at
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FIGURE 1 | Translation from experimental and existing therapeutics to
clinical applications of neural augmentation using optogenetics. (A)
Manipulation of somatosensory codes has been achieved in mouse barrel
cortex, whereby optogenetically perturbing the sensory code caused the
mouse to incorrectly report the location of the real bar as being in the blue
position when the correct location was the red position (O’Connor et al.,
2013). In a similar manner, directly interfacing into human somatosensory
when an external sensor detects signals that are imperceptible for humans,
such as electromagnetic radiation, may allow for additional sensory
capabilities. (B) Currently, BMI applications only offer the possibility of
open-loop applications, by reading neural activity to drive interfaces.
Optogenetics could potentially extend BMI to provide currently sensory
feedback from the prosthetic back, thus closing the feedback loop (left). This
could be extended to refine motor control (right), by supplying an additional
sensory error which has been proposed to improve motor rehabilitation
following stroke (Wei et al., 2005; Celik et al., 2009). Together, these
applications highlight the potential to develop applications from both animal
models as well as existing applications, such as BMI. Images: prosthetic hand
taken from Patent US Patent App. 10/488,008. Human brain (Wikimedia
Commons); Mouse brain (Green, 1966).
motor rehabilitation following stroke (Wei et al., 2005; Celik
et al., 2009). While these studies have been limited to error
augmentation to gross movements, the spatial specificity of
optogenetics when applied to topological maps presents the
possibility for artificially inducing errors in either amotor-related
cortices, to induce a trajectory bias (Wei et al., 2005), or with
more difficulty, to generate errors related to subject’s knowledge
of the current state (Celik et al., 2009).
One requirement for a closed-loop system is the need for
optimizing information transfer rates. Motivated by the need
for more efficient methods for patients with neuromuscular
disorders, much effort has been dedicated to developing
classification schemas to optimize information transfer rates
(Wolpaw et al., 2002; McFarland et al., 2003). Many BMIs
currently use EEG, which is slower and population based,
or implanted cortical electrodes, which improve on temporal
and spatial resolution for decoding neural activity but lack
encoding specificity, particularly for neural stimulation. By
replacing this with optogenetics, it becomes possible to record
signals with higher temporal and spatial resolution, thereby
increasing accuracy, as well as stimulating defined cell types
and patterns. This offers the potential of precise decoding
of the activity of neural ensembles, which has implications
beyond clinical BMI applications. In principle, the provision
of a high bit-rate bidirectional interface between the brain and
a computer would enable additional computational operations
to be outsourced to a computer. This includes, for instance,
possibilities ranging from decoding encrypted content using
visualized passcodes, through to the external storage of memories
(Berger et al., 2011). However, the development of such
applications requires human subjects, and is thus unlikely to
achieve ethical approval for these applications alone. Yet, as
with electrode-based interfaces, such applications of optogenetic
brain-machine interfaces may emerge as a by-product of clinical
research.
In addition to memory, there is already some evidence
that optogenetics can successfully alter cognitive and behavioral
processing. In a recent study, it was possible to induce a negative
behavior similar to obsessive-compulsive disorder (OCD) by
targeting cortico-striatal projections, thus inducing behavior
directly (Ahmari et al., 2013). The aim of the study was to test
whether hyperstimulation of this pathway in mice would result
in OCD-like behavior, which is unable to be tested clinically,
but their success demonstrates that optogenetic intervention
can change behavioral characteristics—with changes lasting up
to weeks after the experiment ended. Similarly, another recent
report investigated the role of serotonergic neurons within
the dorsal raphe nucleus, which were already known to be
involved in signalling reward. Using optogenetics, Miyazaki et al.
(2014) established that mice extended their waiting time with
a probability that inversely correlated with the delay before
serotonergic neurons were optogenetically activated, leading
them to conclude that precisely timed stimulation of serotonin
neuron correlates with the willingness to wait—a quality they
referred to as “patience.”
From sensory and motor augmentation, through to
modification of cognitive and behavioral traits, optogenetics
uniquely has the specificity and precision to affect the neural
correlates of these processes and to improve them. Yet for all
the promise, this is still hampered by a common limitation: a
deep understanding of the topographic mapping of information
onto the relevant cortical areas and of the fine-grained neural
coding of cognitive signals. Considerable progress in optogenetic
augmentation of cognitive capacity will therefore have to wait
for a more detailed understanding of “the cognitive neural code”
before augmented neural function becomes an achievable reality.
4. CLINICAL CHALLENGES FOR
OPTOGENETIC AUGMENTATION
Despite the very clear advantages that optogenetics offers for
controlling neural activity, there are also four technical hurdles
that exist before its translation to applied clinical use. These are
opsin delivery, opsin choice, illumination strategies and optical
actuators. Additionally, the ethical and regulatory hurdles raised
by augmentation using optogenetics are manifold.
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To date, the majority of optogenetic studies use mice, due
to the large number of transgenic murine strains available
for cellular targeting (e.g., using Cre recombinase, Madisen
et al., 2012, and now intersectional genetic targeting approaches,
Madisen et al., 2015). Cre recombinase targeting is however
inapplicable in humans, thus an alternative method must be
used. The most likely remaining candidate for opsin delivery
is viral transfection, which uses viruses as carriers, such as
adeno-associated viruses (AAV) or lentiviruses. Recent studies
have confirmed that opsin delivery via AAV can be performed
in species other than mice, including rats (Bass et al., 2010;
Witten et al., 2010; Stefanik et al., 2013) and primates (Han,
2012). Furthermore, AAVs have been approved by the FDA
for use in clinical trials (1995 for the first application; 2005
for the first application within the brain; Carter, 2005), thus
removing a key hurdle for the use of optogenetics in clinical trials.
An alternative strategy uses transplantable cells deliver opsins
to marked sites (Weick et al., 2010); although this approach
can suffer from extended opsin expression time, it raises the
intriguing prospect of incorporating optogenetic addressability
into new tissue formed by stem cell approaches to brain repair.
Different opsin variants have been shown to modify neuronal
firing patterns in different ways. The insertion of CatCh,
an excitatory opsin, prevented spikes following an initial
volley spiking in fast-spiking cells, while the same cell class
demonstrated sustained spiking when another actuating opsin,
channelrhodopsin fast receiver (FR), was used instead (Mattis
et al., 2012). The improvement of opsin design is ongoing,
aiming for faster kinetics, preferred excitation wavelength,
increased sensitivity and faster recovery (Lin, 2011). Among
the newer generation of opsins are Chronos, a improved
channelrhodopsin (Klapoetke et al., 2014), and JAWS, a red-
shifted light-driven chloride pump (Chuong et al., 2014). As
exhaustively testing all combinations of opsins and neuronal
populations is impossible, this issue highlights the importance of
good opsin characterization and models for determining suitable
opsin-neuron combinations within any given neural circuit.
In this, the development of accurate computational models of
neurons, circuits (Potjans and Diesmann, 2014) and opsins
(Nikolic et al., 2009; Grossman et al., 2013; Nikolic et al., 2013)
will be vital for refining the matching of opsin to neuronal
population and illumination protocols (Lin, 2011; Mattis et al.,
2012; Jarvis et al., 2014).
A more practical concern is the light source, which can
either be externally located or implantable. Similarly to the
limitations that have troubled other biomedical devices, such as
electrical DBS or retinal implants, both external and implantable
devices have limitations: respectively, these are the need to open
a pathway through the skin, and the need to provide power,
either by an implanted battery or by transcutaneous transmission
(O’Handley et al., 2008). Further practical limitations apply due
to the need to deliver light to structures that can be located
deep within the brain. Light penetration through tissue is limited
by scattering. This is already limiting in mice (although new
redshifted opsins such as ReaChR Lin et al., 2013 and JAWS
Chuong et al., 2014, are increasing the achievable penetration
depth). This factor becomes a major hurdle upon scaling up to
human subjects. One approach to the solution of this problem
is to target deep brain structures using penetrating optrodes,
analogous to the use of penetrating electrodes in DBS. An
additional issue that may arise in larger animals is to ensure the
uniform spread of light over a wide area of tissue, i.e., ensuring
that the falloff rate for illumination is sufficiently low such that
the entirety of targeted areas are illuminated, whilst avoiding
tissue damage due to overheating (Han, 2012).
Additionally, it is currently unclear that actuating an entire
population of cells will be sufficient to provide useful input to the
brain.While population firing rate codes have been demonstrated
in some cortical areas (Georgopoulos et al., 1986), even firing rate
codes may be “labeled line” codes in which cell identity matters
(Montani et al., 2007; Schultz et al., 2009). Processing in some
brain circuits has been proposed to occur through precise phase
latencies within oscillatory activity (Engel et al., 2001), and the
mechanisms underlying coding of cognitive information within
the brain are still far from clear. For these latter schemes, whole
field illumination of neurons in even a class-specific manner will
clearly not be effective. Instead, only a specific subset of cells, such
as an orientation column, should be targeted which is currently
impossible using whole-field illumination.
This leads directly on to the last significant technical hurdle for
clinical optogenetics: how can a large number of neurons within
a population be driven with precise spatial, and defined temporal,
resolution? The majority of optogenetic experiments to date have
employed single photon excitation of opsins, typically supplied
by a light emitting diode or fibre-coupled laser. The disadvantage
with such approaches is that optogenetic activation is then not
spatially limited, and consequently all opsin-expressing cells
within an area of tissue are affected (Figure 2A). For some
optogenetic applications, this may not be sufficient. Instead, it
is critical to target subpopulations of neurons, then alternatives
are available, such as the use of techniques such as multi-site
light emitting diode arrays (Grossman et al., 2010). However,
such approaches are in practice limited to the retina or in vitro
preparations, as they provide negligible to no confinement within
the axial plane (Figure 2B).
Two further possibilities exist that exploit optical technology
to provide precise spatiotemporal patterning. The first is
multiphoton excitation (Rickgauer and Tank, 2009), typically 2-
photon (2P), which is spatially confined enough to allow the
optical activation of individual cells. By using the interaction of
two photons of longer wavelengths, which have less scatter, a
small point spread function (PSF) is created that is constrained
in the axial as well as lateral dimension (Figure 2C) and
can be relocated in space, thus activating individual neurons
throughout the tissue volume. However, as the PSF is typically
smaller than the soma, 2P excitation is insufficient to initiate
an action potential without scanning within the cell—which in
turn reduces the temporal resolution of the technique (Rickgauer
and Tank, 2009). Another recent approach uses wavefront
shapingmethods, such as digital holography or generalized phase
contrast (Figure 2D), and by manipulating the phase of light
with a spatial light modulator, create a defined spatial pattern
of light that can similarly scan multiple neurons in a volume
of tissue (Papagiakoumou et al., 2010; Oron et al., 2012). Both
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FIGURE 2 | Activating neurons to drive activity. (A) Whole field illumination via diode, either located at the cortical surface or inserted within the tissue. In both
instances, all neurons within the illuminated area are activated. (B) An array of photodiodes illuminates subpopulations in the lateral plane, illustrated here in
combination with opsin specificity for only one class of neuron. However, targeting is not constrained in the axial dimension and likewise drives multiple neurons within
a column corresponding to each individual diode. (C) Multiphoton excitation results in a spatially constrained point spread function (PSF) in lateral and axial planes.
Here, the 2P beam is targeted for the first neuron, whose soma is significantly larger than the PSF thus requiring scanning the neuron and increasing the dwell time.
Driving other selected neurons within the population (2–6) is performed sequentially. (D) Digital holography utilizes wavefront shaping, in which a spatial light modulator
alters the phase of beams in order to create multiple PSFs, allowing multiple neurons to be simultaneously but independently driven.
multiphoton excitation and wavefront shaping are limited at a
rate proportional to the population size of the neurons to be
targeted. Furthermore, despite being tested in vivo as well as
in vitro, they only exist for head-fixed subjects, thus currently
preventing its application for experiments including freely
behaving subjects. Yet, as precise spatiotemporal patterning is
likely to be necessary to take advantage of the full capabilities
of optogenetic manipulation of brain circuitry, particularly
where synaptic plasticity mechanisms are involved, this area of
technological development is one to watch closely.
In addition to technical hurdles, the regulatory requirements
for bringing optogenetics to clinical reality are also substantial.
As discussed, the FDA has already cleared the use of AAV-
delivered, providing an option for opsin delivery (Carter, 2005).
However, opsin expression application in human, in which
light-sensitive proteins are inserted into cellular membrane
via genetic manipulation, has not been cleared and would
likely require similar clearance to other gene therapies. This is
compounded with the difficulty in determining the correct levels
of opsin expression, as overexpression has been demonstrated
to have cytotoxic effects. The FDA has recently cleared an
application for optogenetic gene therapy for the treatment of
RP, which will allow clinical trials in humans to commence
(Francis et al., 2013; RetroSense, 2015). The treatment aims to
restore photosensitivity of photoreceptors, bypassing the need
for a separate light activation source. This is in contrast to
cortical optogenetic application which would additionally require
implanted optrodes, placing them in the highest band for both
the FDA and EU regulatory approval. In addition to the usual
considerations associated with implantable device, implanted
optical devices have an additional constraint of minimization
of energy via heat lost to prevent tissue damage. Determining
the distribution of energy by optical delivery devices has been
modeled (Ozden et al., 2013), however althought the FDA have
determined power limits for MRI that allow temperature changes
of 1◦C, there are, as yet, no limits for power limits for chronically
implanted optrodes (Ozden et al., 2013). For chronic usage, this
may require significantly lower limits for power, thus restricting
the range of illumination.
Finally, the ethical considerations that surround
neuroenhancement are substantial and have been discussed
elsewhere, including in this issue (Clark, 2014; Shook et al.,
2014). Many of the same arguments for enhancement of
cognitive abilities via pharamacological (Hyman, 2011),
transcranial or electrical means are similarly applicable here for
optogenetics: the development of a cognitive “arms race"; the
question of who is in control of the augmenting device; and
safety, both due to unintended consequences of manipulating
neural activity as well as from the treament itself. The latter
is particularly pertinent for the application of optogenetics, as
it is highly invasive, requiring both manipulation of genetic
material as well as the subcranial placement of devices to
provide optical activation. This raises the ethical cost of
optogenetics, such that its capacity for neuroenhancement
must be substantially higher in comparison to other treatments
to warrant its use preferentially. However, this provides
an ethical impasse: how should these critera be tested and
developed for optogenetics, while the risk and invasiveness
of clinical optogenetics remains high? It may well be that
such clinical trials may emerge as a by-product of optogenetic
therapies for treatment of existing dysfunction or BMIs, rather
than augmentation; or instead that it will ultimately require
the use of similar but separate therapies, such as targeted
nanoparticles (Carvalho-de Souza et al., 2015) which have the
same advantages as optogenetics, but with diminished risks, to
make neuroenhancement not only ethically more attractive but
also clinically attainable.
5. CONCLUSION
Optogenetics has opened up a variety of new experimental
paradigms in neuroscience. Its key advantage lies in the ability
to target neuronal populations with precise spatiotemporal
activation with immediate and reversible effect, which has
been advantageous for untangling the contribution of neuronal
populations in neural processing in both anatomical and
behavioral studies (Tye and Deisseroth, 2012). These advantages
also place optogenetics as a well-suited tool to assist in the
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development of neurological therapies and, correspondingly,
neural enhancements.
The application of optogenetics as a tool for direct use
in neural modulation itself is less certain. The technological
development of optogenetics is still in progress, with opsin
molecular engineering, opsin delivery and optical stimulation
techniques advancing rapidly, which will undoubtedly increase
the precision of optogenetics and with it, our ability to
manipulate neural circuits. However, the translation of
optogenetics from research tool to clinical application has
additional stipulations, particularly for its use in humans.
From the challenges of opsin delivery to the difficulties in
optically driving neurons with implantable devices, applying
optogenetics outside of research remains a remote possibility
in the foreseeable future. Yet in themselves, these elements
are not the most significant constraint on the application of
optogenetics for neural augmentation, which is instead our
understanding of the neural codes that we are attempting to
adapt. In the meantime, optogenetics offers a viable possibility
for the development of novel neural therapies, by providing
a robust capability to technically refine stimulation protocols
and evaluate the effect of modulating activity levels of different
neuronal populations.
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